Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3576
Gene Symbol: CXCL8
CXCL8
0.400 Biomarker disease BEFREE Metformin interrupts bidirectional signaling between tumor and mesothelial cells by blocking OvCa cell TGF-β signaling and mesothelial cell production of CCL2 and IL-8. 31851935 2019
Entrez Id: 6347
Gene Symbol: CCL2
CCL2
0.100 Biomarker disease BEFREE Metformin interrupts bidirectional signaling between tumor and mesothelial cells by blocking OvCa cell TGF-β signaling and mesothelial cell production of CCL2 and IL-8. 31851935 2019
Entrez Id: 3091
Gene Symbol: HIF1A
HIF1A
0.100 Biomarker disease BEFREE Disruption of HIF1α-driven IL-8 signaling in mesothelial cells by metformin results in reduced OvCa invasion in an organotypic 3D model. 31851935 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status. 31851060 2019
Entrez Id: 3902
Gene Symbol: LAG3
LAG3
0.010 AlteredExpression disease BEFREE Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status. 31851060 2019
Entrez Id: 83737
Gene Symbol: ITCH
ITCH
0.010 Biomarker disease BEFREE Circular RNA itchy E3 ubiquitin protein ligase (circ-ITCH), a novel circular RNA originated from several exons of ITCH and located on chromosome 20q11.22, was proved to be declined in many malignant tumors, such as melanoma and ovarian cancer, resulting in tumor occurrence and progression. 31843532 2019
Entrez Id: 400629
Gene Symbol: TEX19
TEX19
0.010 AlteredExpression disease BEFREE TEX19 was significantly upregulated in OC which correlated to higher TNM stage, lymph node involvement, and invasiveness. 31843525 2020
Entrez Id: 100505881
Gene Symbol: MAGI2-AS3
MAGI2-AS3
0.010 Biomarker disease BEFREE Long Non-Coding RNA MAGI2-AS3 is a New Player with a Tumor Suppressive Role in High Grade Serous Ovarian Carcinoma. 31842477 2019
Entrez Id: 104472715
Gene Symbol: SNHG14
SNHG14
0.020 Biomarker disease BEFREE In this research, lncRNA SNHG14 was studied to identify its role in the metastasis of ovarian cancer. 31841176 2019
Entrez Id: 54487
Gene Symbol: DGCR8
DGCR8
0.020 Biomarker disease BEFREE In summary, SNHG14 could enhance cell migration and invasion via upregulating DGCR8 in ovarian cancer. 31841176 2019
Entrez Id: 406931
Gene Symbol: MIR139
MIR139
0.060 AlteredExpression disease BEFREE We aimed to investigate the expression and function of miR-139 in OC. 31839712 2019
Entrez Id: 538
Gene Symbol: ATP7A
ATP7A
0.020 Biomarker disease BEFREE It was revealed via an in vivo study that miR-139 remarkably inhibited the growth of malignancies by downregulating ATP7A in nude mice. miR-139 represses the development of malignancies in OC by directly targeting ATP7A, offering an innovative approach for molecular therapy of OC. 31839712 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation disease BEFREE We used CRISPR-DS to deeply sequence (mean Duplex depth ~3000×) the TP53 gene in 30 Pap tests from 21 women without cancer and 9 women with serous ovarian carcinoma with known TP53 driver mutations. 31839337 2020
Entrez Id: 406991
Gene Symbol: MIR21
MIR21
0.100 Biomarker disease BEFREE MiR-21 modulates the polarization of M2 macrophages and increases the effects of M2 macrophages on promoting the chemoresistance of ovarian cancer. 31837336 2020
Entrez Id: 7849
Gene Symbol: PAX8
PAX8
0.100 AlteredExpression disease BEFREE PAX8 expression in high-grade serous ovarian cancer positively regulates attachment to ECM via Integrin β3. 31832016 2019
Entrez Id: 3690
Gene Symbol: ITGB3
ITGB3
0.050 AlteredExpression disease BEFREE PAX8 expression in high-grade serous ovarian cancer positively regulates attachment to ECM via Integrin β3. 31832016 2019
Entrez Id: 2317
Gene Symbol: FLNB
FLNB
0.010 Biomarker disease BEFREE Taken together, LncRNA-ROR promoted EMT by the miR-145/FLNB regulatory axis in ovarian cancer, providing a potential therapeutic target for ovarian cancer. 31829305 2019
Entrez Id: 3624
Gene Symbol: INHBA
INHBA
0.010 Biomarker disease BEFREE In addition, knockdown of INHBA in cancer cells impaired cancer xenograft growth through reducing OC stromal fibroblast activation <i>in vivo.</i> Further results confirmed that Smad2 signaling pathway was involved in INHBA-induced stromal fibroblast activation, and inhibiting this pathway could effectively reverse activation of stromal fibroblasts. 31827640 2019
Entrez Id: 607
Gene Symbol: BCL9
BCL9
0.320 Biomarker disease BEFREE BCL9 promotes the development of ovarian cancer. 31827404 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 Biomarker disease BEFREE Using cell lines representative of P53 wild-type ovarian cancer (A2780), and P53 mutant ovarian cancer (SKOV3), cells were implanted in the flank of athymic nude female mice. 31827119 2019
Entrez Id: 161003
Gene Symbol: STOML3
STOML3
0.010 Biomarker disease BEFREE In conclusion, SRO-91 analog effects on tumor dissemination and its safety regarding non-cancerous (normal) cells are encouraging findings a promising drug for the treatment of ovarian cancer. 31825993 2019
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.800 Biomarker disease BEFREE Comprehensive Profiling of BRCA1 and BRCA2 Variants in Breast and Ovarian Cancer in Chinese Patients. 31825140 2020
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.800 GeneticVariation disease BEFREE Comprehensive Profiling of BRCA1 and BRCA2 Variants in Breast and Ovarian Cancer in Chinese Patients. 31825140 2020
Entrez Id: 83990
Gene Symbol: BRIP1
BRIP1
0.700 GeneticVariation disease BEFREE These findings suggest that novel missense variants within the helicase domain of BRIP1 may confer risk for both breast and ovarian cancer and highlight the importance of functional testing for additional variants. 31822495 2020
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
0.100 Biomarker disease BEFREE Cyclooxygenase 2 may be a potential therapeutic target for the treatment of ovarian cancer. 31822119 2019